Journal News

MCP: Ovarian cancer’s dark signaling pathways

John Arnst
January 01, 2018

Ovarian cancer is considerably rarer than lung and breast cancer, but it is the seventh-most common cancer in women, and in 2012, 239,000 new cases were diagnosed worldwide. The most common subtype of ovarian cancer, high-grade serous ovarian adenocarcinoma, or HGSOC, is also the most lethal, with a five-year survival rate of less than 40 percent despite high vulnerability to early treatment with chemotherapy.

This image from the 1905 text, “The diagnosis of diseases in women” by Findley Palmer, shows an adenocarcinoma of the ovary in which, according to the caption, “(t)he ovary is enlarged to the size of a child’s head.”
WIKIMEDIA COMMONS/THE LIBRARY OF CONGRESS

The mortality rate is high largely because HGSOC tumors tend to shed small spheroids early and prolifically, spreading through the peritoneal fluid in the abdominal cavity to the pelvis and nearby organs. The spheroids, together with tumor-associated T cells and macrophages derived from nearby tissues and the circulation, then manufacture a microenvironment of signaling factors that promote cancer progression, immunosuppression and resistance to chemotherapies. This hostile bubble is maintained by obscure signaling mechanisms between the different cell types, and disrupting them with existing drugs may be a way to fight this notably aggressive form of cancer.

In a paper published in the journal Molecular & Cellular Proteomics, researchers at Philipps University in Marburg, Germany, have analyzed the proteome and transcriptome of the microenvironment of tumors in the abdominal fluid taken from women with HGSOC. Using state-of-the-art proteotranscriptomic techniques, the researchers have thrown light on the signaling networks and uncovered associations between factors expressed by the tumors and the likelihood of patient survival.

“We came up with a signaling map between tumor cells, macrophages and T cells,” said Rolf Müller, senior author on the paper, “and could now analyze and determine which cells secrete which mediators and on which cells these mediators act.”

Müller and colleagues previously had developed a signaling map based on the RNA, or transcriptome, expressed in tumor cells and related macrophages, but they wanted to expand their analyses to encompass the proteome and the aggregate of secreted molecules known as the secretome. Analyses of the transcriptome, proteome and secretome, Müller said, “all have their limitations on their own, (but) you can combine them to obtain something really meaningful.”

With a signaling map, Müller and colleagues were able to confirm several known signaling pathways and identify two new subgroups of macrophages, which they named B and G for their respective presence in patients with bad or good prognoses.

Müller and colleagues found that tumor spheroids and macrophages taken from patients with an estimated short survival time, based on the presence of additional factors, produced proteins that support remodeling of extracellular matrices and immunosuppression, which are both key for further cell proliferation. In contrast, macrophages taken from patients with an estimated longer survival time expressed cytokines linked to the activation and attraction of tumor-fighting effector T cells.

While clinical trials are still beyond the horizon, Müller and first author Thomas Worzfeld said they and their colleagues are interested in exploring the gamut of available pharmaceuticals that can interrupt the signaling within tumors as an alternative to disrupting extracellular communication pathways.

“There’s a drug to block almost any important intracellular signaling pathways nowadays,” Müller said, “and it would be interesting to see what the important signals are and on what intracellular signaling pathways the signals converge so that we can also block these interactions. That is something we really would like to work on in the future.”

John Arnst

John Arnst is a science writer for ASBMB Today.

Join the ASBMB Today mailing list

Sign up to get updates on articles, interviews and events.

Latest in Science

Science highlights or most popular articles

A small army of researchers races to build a coronavirus interactome
News

A small army of researchers races to build a coronavirus interactome

April 01, 2020

Scientists at eight institutions in the U.S. and Europe have used a protein interaction map to identify 69 drugs that might work against SARS-CoV-2, the virus that causes COVID-19.

Parkinson's  Awareness Month
Health Observance

Parkinson's Awareness Month

April 01, 2020

It is the second-most common progressive neurodegenerative disease, occurring in 1% of people over the age of 60 and in 5% of people over 85.

Multiomics meets antimalarials
Journal News

Multiomics meets antimalarials

March 31, 2020

Researchers in Australia use an innovative multiomics approach to analyze a new drug against malaria parasites.

From the journals: JLR
Journal News

From the journals: JLR

March 31, 2020

Topics include the role of HDL and Smo in inhibiting beta-cell apoptosis, lipid asymmetry in a plasma membrane and apolipoproteins and dementia risk.

Researchers retool genomics labs to provide COVID-19 testing
News

Researchers retool genomics labs to provide COVID-19 testing

March 30, 2020

The pipetting robots are already in place, but that doesn’t make it easy. Here's how academic laboratories are quickly pivoting to provide testing for the coronavirus.

Research on a budget
Essay

Research on a budget

March 30, 2020

As a professor at a small university, Peter Lyons has developed ways of reaching his research goals with limited funding, and he shares some of them here.